Clinical Trials Browser

INDUSTRY × Myeloproliferative Disorders × Ipilimumab × Clear all

NCT05444530 2025-07-20

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase 1 Completed

Myeloproliferative Disorders